Peptide-mediated cancer targeting of nanoconjugates

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 3, Issue 3, 2011, Pages 269-281

  Raha, Sumita ^a   Paunesku, Tatjana ^a   Woloschak, Gayle ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID POLYMERS; CANCER RESEARCH; CANCER-TARGETING; IN-CELL; IN-VITRO; IN-VIVO; MULTIPLE BINDING SITES; NANOCONJUGATES; NANOPARTICLE SURFACE; ORGANIC MATERIALS; PLURIPOTENT; SMALL MOLECULES; TARGET BINDING;

AMINO ACIDS; BINDING SITES; BIOCHEMISTRY; DISEASES; ORGANIC POLYMERS; PEPTIDES; POLYMERS;

NANOPARTICLES;

ALLATOSTATIN 1; ALPHA INTERMEDIN DERIVATIVE; AMINO ACID; ARGINYLGLYCYLASPARTIC ACID; BOMBESIN; CARBON NANOTUBE; CETUXIMAB; CYSTEINYLGLYCYLLEUCYLISOLEUCYLISOLEUCYLGLUTAMINYLLYSYLASPARAGINYLGLUTAMYLCYSTEIN E; ENTEROTOXIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FOLLICLE STIMULATING HORMONE 33; FOLLITROPIN; HEPATOCARCINOMA TARGETING PEPTIDE; LIPOSOME; MACROGOL; MELITTIN; NANOPARTICLE; PACLITAXEL; PEPTIDE; PEPTIDE CENDR; PEPTIDE F3; PEPTIDE GFE; PEPTIDE LYP 1; POLYMER; SOMATOSTATIN; TRANSACTIVATOR PROTEIN; TRYPTOPHYLISOLEUCYLPHENYLALANYLPROLYLTRYPTOPHYLISOLEUCYLGLUTAMINYLLEUCIN E; TUBULYSIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BINDING SITE; CANCER RESEARCH; CHEMICAL MODIFICATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; MOLECULAR SIZE; NANOBIOTECHNOLOGY; NEOPLASM; PRIORITY JOURNAL; REVIEW; SURFACE PROPERTY;

ANIMALS; DRUG DELIVERY SYSTEMS; NANOCONJUGATES; NEOPLASMS; PEPTIDES; SUBCELLULAR FRACTIONS;

EID: 79953290600     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.121     Document Type: Review

References (65)

1. Arvizo RR, Miranda OR, Thompson MA, Pabelick CM, Bhattacharya R, Robertson JD, Rotello VM, Prakash YS, Mukherjee P. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett 2010, 10:2543-2548.
2. Bartneck M, Keul HA, Zwadlo-Klarwasser G, Groll J. Phagocytosis independent extracellular nanoparticle clearance by human immune cells. Nano Lett 2010, 10:59-63.
3. Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, Muders M, Wang S, Buhrow SA, Safgren SL, et al. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res 2008, 68:1970-1978.
4. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008, 22:315-329.
5. Zhang G, Yang Z, Lu W, Zhang R, Huang Q, Tian M, Li L, Liang D, Li C. Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenograted mice. Biomaterials 2009, 30: 1928-1936.
6. Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X, Chen X, Dai H. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol 2007, 2:47-52.
7. Chanda N, Kattumuri V, Shukla V, Zambre A, Katti K, Upendran A, Kulkarni R, Kan R, Fent P, Casteel GM, et al. Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc Natl Acad Sci 2010, 107:8760-8765.
8. Biju V, Muraleedharan D, Nakayama K, Shinohara Y, Itoh T, Baba Y, Ishikawa M. Quantum dot-insect neuropeptide conjugates for fluorescence imaging, transfection, and nucleus targeting of living cells. Langmuir 2007, 23:10254-10261.
9. Zhang XY, Chen J, Zheng YF, Gao XL, Kang Y, Liu JC, Cheng MJ, Sun H, Xu CJ. Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo. Cancer Res 2009, 69:6506-6514.
10. von Maltzahn G, Ren Y, Park JH, Min DH, Kotamraju VR, Jayakumar J, Fogal V, Sailor MJ, Ruoslahti E, Bhatia SN. In vivo tumor cell targeting with "click" nanoparticles. Bioconjug Chem 2008, 19:1570-1578.
11. Laakkonen P, Akerman ME, Biliran H, Yang M, Ferrer F, Karpanen T, Hoffman RM, Ruoslahti E. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A 2004, 101:9381-9386.
12. Åkerman M, Chan W, Laakkonen P, Bhatia S, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A 2002, 99:12617.
13. Chen X, Wang X, Wang Y, Yang L, Hu J, Xiao W, Fu A, Cai L, Li X, Ye X, et al. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release 2010, 145:17-25.
14. Tu Y, Kim J. selective gene transfer to hepatocellular carcinoma using homing peptide-grafted cationic liposomes. J Microbiol Biotechnol 2010, 20:821-827.
15. Bhirde AA, Patel JG, Zhang GF, Sousa AA, Masedunskas A, Leapman RD, Weigert R, Gutkind JS, Rusling JF. Targeting killing of cancer cells in vivo and in vitro with egf-directed carbon nanotube-based drug delivery. ACS Nano 2009, 3:307-316.
16. Kang B, Mackey M, El-Sayed M. Nuclear targeting of gold nanoparticles in cancer cells induces dna damage, causing cytokinesis arrest and apoptosis. J Am Chem Soc 2010, 132:1517-1519.
17. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, Ruoslahti E. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010, 328:1031-1035.
18. Tan M, Wu X, Jeong E, Chen Q, Lu Z. Peptide-targeted nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging. Biomacromolecules 2010, 11:754-761.
19. Katanasaka Y, Ishii T, Asai T, Naitou H, Maeda N, Koizumi F, Miyagawa S, Ohashi N, Oku N. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78. Int J Cancer 2010, 127:2685-2698.
20. Danhier F, Vroman B, Lecouturier N, Crokart N, Pourcelle V, Freichels H, Jérôme C, Marchand-Brynaert J, Feron O, Préat V. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel. J Control Release 2009, 140: 166-173.
21. Murphy E, Majeti B, Barnes L, Makale M, Weis S, Lutu-Fuga K, Wrasidlo W, Cheresh D. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci 2008, 105:9343.
22. Simberg D, Duza T, Park JH, Essler M, Pilch J, Zhang L, Derfus AM, Yang M, Hoffman RM, Bhatia S, et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci 2007, 104:932-936.
23. Kelly KA, Setlur SR, Ross R, Anbazhagan R, Waterman P, Rubin MA, Weissleder R. Detection of early prostate cancer using a hepsin-targeted imaging agent. Cancer Res 2008, 68:2286-2291.
24. Kelly KA, Bardeesy N, Anbazhagan R, Gurumurthy S, Berger J, Alencar H, DePinho RA, Mahmood U, Weissleder R. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med 2008, 5:e85.
25. Feldherr C, Lanford R, Akin D. Signal-mediated nuclear transport in simian virus 40-transformed cells is regulated by large tumor antigen. Proc Natl Acad Sci U S A 1992, 89:11002-11005.
26. Tkachenko AG, Xie H, Liu Y, Coleman D, Ryan J, Glomm WR, Shipton MK, Franzen S, Feldheim DL. Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug Chem 2004, 15:482-490.
27. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, Weissleder R. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000, 18:410-414.
28. Standley SM, Toft DJ, Cheng H, Soukasene S, Chen J, Raja SM, Band V, Band H, Cryns VL, Stupp SI. Induction of cancer cell death by self-assembling nanostructures incorporating a cytotoxic peptide. Cancer Res 2010, 70:3020-3026.
29. Soman NR, Baldwin SL, Hu G, Marsh JN, Lanza GM, Heuser JE, Arbeit JM, Wickline SA, Schlesinger PH. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest 2009, 119: 2830-2842.
30. Schluep T, Gunawan P, Ma L, Jensen GS, Duringer J, Hinton S, Richter W, Hwang J. Polymeric tubulysin-peptide nanoparticles with potent antitumor activity. Clin Cancer Res 2009, 15:181-189.
31. Edelman M, Clamon G, Kahn D, Magram M, Lister-James J, Line B. Targeted radiopharmaceutical therapy for advanced lung cancer. J Thorac Oncol 2009, 4: 1550-1554.
32. Rajotte D, Ruoslahti E. Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display. J Biol Chem 1999, 274:11593-11598.
33. Porkka K, Laakkonen P, Hoffman JA, Bernasconi M, Ruoslahti E. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci U S A 2002, 99:7444-7449.
34. Hsiao JR, Chang Y, Chen YL, Hsieh SH, Hsu KF, Wang CF, Tsai ST, Jin YT. Cyclic v 6-targeting peptide selected from biopanning with clinical potential for head and neck squamous cell carcinoma. Head Neck 2010, 32:160-172.
35. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A 2009, 106:16157-16162.
36. Tatro JB, Atkins M, Mier JW, Hardarson S, Wolfe H, Smith T, Entwistle ML, Reichlin S. Melanotropin receptors demonstrated in situ in human melanoma. J Clin Investig 1990, 85:1825-1832.
37. Chen J, Cheng Z, Hoffman T, Jurisson S, Quinn T. Melanoma-targeting properties of 99mTechnetium-labeled cyclic α-melanocyte-stimulating hormone peptide analogues. Cancer Res 2000, 60:5649-5658.
38. Okarvi SM, Jammaz IA. Design, synthesis, radiolabeling and in vitro and in vivo characterization of tumor-antigen- and antibody-derived peptides for the detection of breast cancer. Anticancer Res 2009, 29:1399-1409.
39. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer 2010, 46:1271-1277.
40. Giblin M, Sieckman G, Shelton T, Hoffman T, Forte L, Volkert W. In vitro and in vivo evaluation of 177Lu-and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers. Nucl Med Biol 2006, 33:481-488.
41. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002, 8:918-921.
42. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
43. Huang B, Desai A, Tang S, Thomas T, Baker J Jr. The synthesis of ac (RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release. Org Lett 2010, 12:1384-1387.
44. Aouida M, Poulin R, Ramotar D. The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J Biol Chem 2010, 285:6275-6284.
45. Smith GP, Petrenko VA. Phage display. Chem Rev 1997, 97:391-410.
46. Jayanna P, Bedi D, Deinnocentes P, Bird R, Petrenko V. Landscape phage ligands for PC3 prostate carcinoma cells. Protein Eng Des Sel 2010, 23:423-430.
47. Jaboin JJ, Han Z, Hallahan DE. Using in vivo biopanning for the development of radiation-guided drug delivery systems. Methods Mol Biol 2009, 542:285-300.
48. Fievez V, Plapied L, Plaideau C, Legendre D, des Rieux A, Pourcelle V, Freichels H, Jérôme C, Marchand J, Préat V, et al. In vitro identification of targeting ligands of human M cells by phage display. Int J Pharm 2010, 394:35-42.
49. Helm B, Reulen SW, Nijhuis S, de Graaf-Heuvelmans PT, Merkx M, Meijer EW. High-affinity peptide-based collagen targeting using synthetic phage mimics: from phage display to dendrimer display. J Am Chem Soc 2009, 131:11683-11685.
50. Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 2005, 23:1418-1423.
51. Mann DA, Frankel AD. Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J 1991, 10: 1733-1739.
52. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 1996, 271:18188-18193.
53. Avrameas A, Ternynck T, Nato F, Buttin G, Avrameas S. Polyreactive anti-DNA monoclonal antibodies and a derived peptide as vectors for the intracytoplasmic and intranuclear translocation of macromolecules. Proc Natl Acad Sci U S A 1998, 95:5601-5606.
54. Phelan A, Elliott G, O'Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol 1998, 16:440-443.
55. Olson ES, Jiang T, Aguilera TA, Nguyen QT, Ellies LG, Scadeng M, Tsien RY. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci 2010, 107:4311-4316.
56. Tosteson MT, Tosteson DC. The sting: Melittin forms channels in lipid bilayers. Biophys J 1981, 36:109-116.
57. Hartgerink J. Covalent capture: a natural complement to self-assembly. Curr Opin Chem Biol 2004, 8: 604-609.
58. Ulijn RV, Smith AM. Designing peptide based nanomaterials. Chem Soc Rev 2008, 37:664-675.
59. Cui H, Webber M, Stupp S. Self-assembly of peptide amphiphiles: from molecules to nanostructures to biomaterials. Peptide Sci 2010, 94:1-18.
60. Pan H, Myerson JW, Ivashyna O, Soman NR, Marsh JN, Hood JL, Lanza GM, Schlesinger PH, Wickline SA. Lipid membrane editing with peptide cargo linkers in cells and synthetic nanostructures. FASEB J 2010, 24:2928-2937.
61. Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small 2010, 6:12-21.
62. Zolnik BS, González-Fernández A, Sadrieh N, Dobrovolskaia MA. Nanoparticles and the immune system. Endocrinology 2010, 151:458-465.
63. Thurn KT, Brown EMB, Wu A, Vogt S, Lai B, Maser J, Paunesku T, Woloschak GE. Nanoparticles for applications in cellular imaging. Nanoscale Res Lett 2007, 2:430-439.
64. Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, Reubi JC. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008, 49:318.
65. Borgman M, Coleman T, Kolhatkar R, Geyser-Stoops S, Line B, Ghandehari H. Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A′′-DTPA) conjugates show increased kidney accumulation. J Control Release 2008, 132:193-199.